Key Points
- Recursion Pharmaceuticals director Blake Borgeson sold 50,000 shares at an average price of $4.84, generating $242,000. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, leaving him with 6.11 million shares.
- RXRX opened at $4.27 and has a market capitalization of approximately $2.29 billion, while its shares have traded between $2.77 and $7.18 over the past year.
- The company reported a quarterly loss of $0.25 per share and revenue of $7.67 million, both slightly below analyst expectations. Analysts hold a consensus rating of “Hold” with an average price target of $8.06.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Robert Hershberg sold 25,000 shares of the business's stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total transaction of $125,000.00. Following the completion of the transaction, the director directly owned 162,156 shares in the company, valued at $810,780. This trade represents a 13.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Recursion Pharmaceuticals Stock Performance
Shares of NASDAQ RXRX opened at $4.27 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03. The company has a market cap of $2.29 billion, a P/E ratio of -4.11 and a beta of 1.04. The firm's fifty day moving average is $3.52 and its two-hundred day moving average is $3.38. Recursion Pharmaceuticals, Inc. has a 52-week low of $2.77 and a 52-week high of $7.18.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The firm had revenue of $7.67 million during the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same period last year, the firm posted ($0.41) earnings per share. As a group, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.94 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on RXRX. Morgan Stanley set a $5.30 price target on shares of Recursion Pharmaceuticals in a research report on Monday, August 17th. Weiss Ratings restated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Finally, Wall Street Zen raised Recursion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 29th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $8.06.
Read Our Latest Report on RXRX
Institutional Trading of Recursion Pharmaceuticals
Large investors have recently made changes to their positions in the stock. MCF Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the second quarter worth about $27,000. Fund Advisors of America Inc FL bought a new stake in Recursion Pharmaceuticals during the 2nd quarter valued at about $45,000. Integral Investment Advisors Inc. bought a new stake in Recursion Pharmaceuticals during the 1st quarter valued at about $39,000. MQS Management LLC bought a new stake in Recursion Pharmaceuticals during the 1st quarter valued at about $41,000. Finally, Sequoia Financial Advisors LLC boosted its position in Recursion Pharmaceuticals by 51.5% in the 1st quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company's stock valued at $47,000 after buying an additional 5,156 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company's technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.
Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
